TTM Technologies (TTMI) closed the last trading session at $58.45, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $76 indicates a 30% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $3.16. While the lowest estimate of $72.00 indicates a 23.2% increase from the current price level, the most optimistic analyst expe ...

Shares of Tango Therapeutics, Inc. (TNGX) have gained 18.2% over the past four weeks to close the last trading session at $8.9, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13 indicates a potential upside of 46.1%.The mean estimate comprises eight short-term price targets with a standard deviation of $1.31. While the lowest estimate of $11.00 indicates a 23.6% increase from ...

Shares of Enanta Pharmaceuticals (ENTA) have gained 13.7% over the past four weeks to close the last trading session at $12.13, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17.57 indicates a potential upside of 44.9%.The mean estimate comprises seven short-term price targets with a standard deviation of $5.44. While the lowest estimate of $9.00 indicates a 25.8% decline from ...

Group 1 - Sandisk Corporation (SNDK) shares have increased by 17.3% in the past four weeks, closing at $195.96, with a mean price target of $262.54 indicating a potential upside of 34% [1] - The average of 13 short-term price targets ranges from a low of $220.00 to a high of $300.00, with a standard deviation of $23.85, suggesting a potential increase of 12.3% to 53.1% from the current price [2] - Analysts show strong agreement on SNDK's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has risen by 75.9% over the past month, with five estimates increasing and no negative revisions [12] - SNDK holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting exact gains, they can indicate the direction of price movement, which appears to be a good guide [14]

Group 1 - O-I Glass (OI) closed at $12.7, with a 3.3% gain over the past four weeks, and a mean price target of $16.56 suggests a 30.4% upside potential [1] - The average price targets range from $13.00 to $19.00, with a standard deviation of $2.07, indicating variability among analysts' estimates [2] - Analysts have shown increasing optimism about OI's earnings prospects, with a strong agreement in revising EPS estimates higher, correlating with potential stock price movements [11][12] Group 2 - The Zacks Consensus Estimate for the current year has increased by 8.3% over the past month, with four estimates going higher and no negative revisions [12] - OI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a directional guide for price movement [14]

On Holding (ONON) closed the last trading session at $43.3, gaining 2.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $60.68 indicates a 40.1% upside potential.The average comprises 22 short-term price targets ranging from a low of $30.00 to a high of $85.00, with a standard deviation of $10.3. While the lowest estimate indicates a decline of 30.7% from the current price level, ...

Shares of El Pollo Loco Holdings (LOCO) have gained 7.1% over the past four weeks to close the last trading session at $10.24, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.67 indicates a potential upside of 33.5%.The mean estimate comprises three short-term price targets with a standard deviation of $3.79. While the lowest estimate of $11.00 indicates a 7.4% increase from ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Onto Innovation (ONTO) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Onto Innovation currently has an average brokerage recom ...

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?Let's take a look at what these Wall Street heavyweights have to say about Toll Brothers (TOL) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Toll Brothers currently has an average brokerage recommenda ...

Core Insights - Oncolytics Biotech Inc. (ONCY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive shift in earnings estimates which is a significant factor influencing stock prices [1][3][10] Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6] - For Oncolytics Biotech, the Zacks Consensus Estimate for earnings has increased by 13.1% over the past three months, reflecting a positive outlook for the company's earnings [8] Investment Implications - The upgrade to Zacks Rank 2 positions Oncolytics Biotech in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10] - Rising earnings estimates indicate an improvement in the company's underlying business, which is expected to drive the stock price higher [5][10]